Most Recent Annual Report
2019 Annual Report and Form 10K

Order Free Hardcopy
You can request a free hardcopy of this report mailed to you by clicking the button below.
You can request a free hardcopy of this report mailed to you by clicking the button below.
Puma Biotechnology, Inc., a development stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of products for the treatment of various forms of cancer. Its drug candidates include PB272 (neratinib (oral)) for the treatment of advanced breast cancer patients, non-small cell lung cancer patients, and patients with HER2 mutation-positive solid tumors; and PB272 (neratinib (intravenous)) for the treatment of advanced cancer patients.